Circassia appoints industry veteran as COO

12 August 2019

UK biotech Circassia Pharmaceuticals (LSE: CIR) today announced the appointment of Jonathan Emms to the newly-created role of chief operating officer (COO).

As COO he will further strengthen Circassia’s commercial focus and lead the company’s global commercial strategy and operational management. He will also join the company’s Board as an Executive Director when he joins Circassia on 2 September 2019.

At the same time Circassia’s senior vice president of R&D, Dr Rod Hafner, will step down from the board after 11 years as a Director, reflecting the company’s commercial focus now the approval process for Duaklir (formoterol fumarate dihydrate/aclidinium bromide) and Tudorza (aclidinium bromide inhalation powder] supplemental New Drug Application (sNDA) are complete. He will remain a key member of Circassia’s senior management team and will continue in his role leading the Circassia’s business development, supply chain, medical affairs, regulatory and quality activities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK